Boehringer Ingelheim and IBM bring blockchain to clinical trials

Boehringer Ingelheim and IBM Canada are using blockchain technology for the first time in a clinical trial setting to test the technology’s trial management capabilities.

“We recognized that the current processes to ensure the quality of clinical trials are frequently inadequate and clinical trial records are often erroneous or incomplete, putting patient safety at risk,” ​Uli Brödl, VP, medical and regulatory affairs, Boehringer Ingelheim told us

Blockchain technologies will test out how such innovations can impact the trial ecosystem and bring forward patient empowerment through patient consent, secure health data exchange, and patient engagement.

"We've been using blockchain in other industries, and we are now investigating how we can use this technology to give Canadian patients the same level of security and trust when it comes to their personal health information,”​ said Claude Guay, general manager, IBM Services, IBM Canada in a statement.

The use of blockchain in clinical trials is also expected to improve the “validity or reputation of the trial due to improved recruitment, retention, speed, and quality of the trial,”​ Brödl added.

Financial terms of this agreement have not been disclosed. Brödl also told us that further details of the trial, including the number of participants, and trial design will be shared later this year.

Blockchain’s real-time visibility​

When using blockchain technology, data cannot be deleted and all changes are tracked.

According to a recent report​, 60% of industry executives are planning to implement blockchain solutions in the coming years, and while the still in the early stages of implementation, several companies have begun using the technology.

Among those using blockchain is Scientist.com, an online marketplace for clinical development needs, which added a blockchain​ technology offering, DataSmart, to protect data throughout the drug development process.

Alpha Genesis​ also is exploring the use of blockchain technology in its primate research activities to boost transparency and traceability.

Additionally, Certara is using blockchain​ to expand its research in transparency and disclosure. The company’s regulatory sciences division, Synchrogenix, collaborated with Hedera Hashgraph in order to develop a platform that offers a public ledger that enables develops to build decentralized applications.

A report by BIS Research​ estimated that blockchain use in health care is estimated to grow to more than $5.16bn by the end of 2025.

source: outsorcing- pharma.com

Legal disclaimer: The insight, recommendations and analysis presented here are based on corporate filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. They are presented for the purposes of general information only, and all the information belongs to the original publishers. These may contain errors and we make no promises as to the accuracy or usefulness of the information we present. You should not make any investment decision based solely on what you read here.